Open AccessMYCOBACTERIOSIS OF THE RESPIRATORY SYSTEM: EPIDEMIOLOGY, MICROBIOLOGY AND CLINICAL ASPECTS OF DIAGNOSIS
Author(s) -
Lidia Guntupova,
S. E. Borisov,
Marina Makarova,
E. N. Hachaturyants
Publication year - 2012
Publication title -
èpidemiologiâ i infekcionnye bolezni
Language(s) - English
Resource type - Journals
eISSN - 2411-3026
pISSN - 1560-9529
DOI - 10.17816/eid40627
Subject(s) - medicine , sputum , rifampicin , isoniazid , bronchoalveolar lavage , microbiology and biotechnology , tuberculosis , capreomycin , mycobacterium fortuitum , dermatology , pathology , lung , mycobacterium , biology , ethambutol
Scientific and Clinical Antituberculosis Center, Department of Health Care of the city of Moscow, ul. Stromynka 10, Sokol'Niki, Moskva 107014. In 40 patients (with no clinically significant immunosuppression) according to the criteria of the American Thoracic Society, pulmonary mycobacterioses (MAC - 35%, M. kansasii - 25%, M. xenopi - 20%, M. fortuitum - 12,5% и M. chelonae - 7,5%) have been diagnosed. In 95% of patients acute clinical symptomatology with polymorphic radiographic findings has been noted. The constant and massive non-tuberculosis mycobacteria (NTMB) excretion was noted. With fluorescent microscopy acid-fast mycobacteria (AFM) were identified from sputum in 62.5% patients, in 22.5% of patients AFM were found in bronchoalveolar lavage fluid. Cultural analysis of sputum processed by broth dilution method permitted to isolate NTMB in 65%, including in 50% - two times or more. In a solid medium sputum cultures with growth of NTMB were isolated in 45%, including 20% - two times or more. In 10.0% NTMB were isolated when plated on solid media operating material. M. fortuitum, M. chelonae and MAC are the most resistant to anti-TB drugs: M. fortuitum - to all major drugs series, M.chelonae - to all major drugs and a number of reserve drugs, including fluoroquinolones) and MAC (resistant to both isoniazid and rifampicin in 92.9% of cases including, in combination with fluoroquinolones and kanamycin, or capreomycin - in 64.3%)